| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 37, 520-526, Copyright © 1991 by American Association for Clinical Chemistry
BJ Oberhardt, SC Dermott, M Taylor, ZY Alkadi, AF Abruzzini and NJ Gresalfi
Cardiovascular Diagnostics, Inc., Research Triangle Park, NC 27709.
Rapid coagulation and fibrinolysis assays suitable for use with an imprecisely measured sample volume (either whole blood or plasma) have been developed, utilizing a technology based on paramagnetic iron oxide particles (PIOP) that move in response to an oscillating magnetic field. PIOP are combined with appropriate test reagents for clotting and thrombolysis assays and formulated as dry reagents within a capillary test chamber. The minima and maxima of the PIOP oscillations define a two-sided waveform that provides kinetic information on fibrin polymerization and lysis. Subject to the chemistry of the dry reagent formulation, the resulting waveform can be used to define clotting time, lysis onset time, or fibrinogen variables. Applications to one- stage prothrombin time and one-stage activated partial thromboplastin time tests have yielded assays with consistently good correlations with other test methods. Applications to fibrinolysis studies have yielded global assays of thrombolytic activity, in that the assay results reflect the interactions of multiple factors associated with the effectiveness of thrombolytic therapy. Depending on the components utilized in a particular reagent formulation, one can derive information about the activity of such factors as fibrinogen, plasminogen, and related inhibitors, as well as the lytic agent being administered. Use of these assays in a clinical setting should provide a rapid, convenient alternative to conventional testing of coagulation variables and a reliable method for monitoring thrombolytic therapy.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  S. A Spinler, E. A Nutescu, M. A Smythe, and A. K Wittkowsky Anticoagulation Monitoring Part 1: Warfarin and Parenteral Direct Thrombin Inhibitors Ann. Pharmacother., June 1, 2005; 39(6): 1049 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1633 - 1652. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy Circulation, April 1, 2003; 107(12): 1692 - 1711. [Full Text] [PDF]
|
|
|
|
 |
|
 D A Fitzmaurice, E T Murray, K M Gee, T F Allan, and F D R Hobbs A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management J. Clin. Pathol., November 1, 2002; 55(11): 845 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Giavarina, M. Carta, A. Fabbri, J. Manfredi, E. Gasparotto, and G. Soffiati Monitoring high-dose heparin levels by ACT and HMT during extracorporeal circulation: diagnostic accuracy of three compact monitors Perfusion, January 1, 2002; 17(1): 23 - 26. [Abstract] [PDF]
|
|
|
|
 |
|
 D A Fitzmaurice and S J Machin Recommendations for patients undertaking self management of oral anticoagulation BMJ, October 27, 2001; 323(7319): 985 - 989. [Full Text] [PDF]
|
|
|
|
 |
|
 B. McD. Duxbury and L. Poller State-of-the-Art Review: The Oral Anticoagulant Saga: Past, Present, and Future Clinical and Applied Thrombosis/Hemostasis, October 1, 2001; 7(4): 269 - 275. [Abstract] [PDF]
|
|
|
|
 |
|
 R C Tait Anticoagulation in patients with thromboembolic disease Thorax, September 1, 2001; 56(90002): ii30 - 37. [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Ambrose, C. A. Parvin, E. Mendeloff, and L. Luchtman-Jones Evaluation of the TAS Analyzer and the Low-Range Heparin Management Test in Patients Undergoing Extracorporeal Membrane Oxygenation Clin. Chem., May 1, 2001; 47(5): 858 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wallock, W. P Jeske, M. Bakhos, and J. M Walenga Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test Perfusion, March 1, 2001; 16(2): 147 - 153. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Ansell, J. Hirsh, J. Dalen, H. Bussey, D. Anderson, L. Poller, A. Jacobson, D. Deykin, and D. Matchar Managing Oral Anticoagulant Therapy Chest, January 1, 2001; 119(1_suppl): 22S - 38S. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Fitzmaurice, F. D. R. Hobbs, E. T. Murray, R. L. Holder, T. F. Allan, and P. E. Rose Oral Anticoagulation Management in Primary Care With the Use of Computerized Decision Support and Near-Patient Testing: A Randomized, Controlled Trial Arch Intern Med, August 14, 2000; 160(15): 2343 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Oberhardt, P. D. Mize, and C. G. Pritchard Point-of-care fibrinolytic tests: the other side of blood coagulation Clin. Chem., September 1, 1997; 43(9): 1697 - 1702. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
